{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mizushige T"],"funding":["NIDDK NIH HHS"],"pagination":["E1800"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5133801"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(11)"],"pubmed_abstract":["This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5-40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (<i>p</i> < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<-50%) and non-responders (≥-50%), and a logistic analysis of urinary angio"],"journal":["International journal of molecular sciences"],"pubmed_title":["Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients."],"pmcid":["PMC5133801"],"funding_grant_id":["R01 DK072408"],"pubmed_authors":["Tomoda F","Mizushige T","Morimoto S","Hitomi H","Nishijima Y","Kobori H","Kohno M","Nishiyama A"],"additional_accession":[]},"is_claimable":false,"name":"Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.","description":"This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5-40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (<i>p</i> < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<-50%) and non-responders (≥-50%), and a logistic analysis of urinary angio","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Oct","modification":"2025-04-03T23:23:37.734Z","creation":"2019-03-27T02:30:31Z"},"accession":"S-EPMC5133801","cross_references":{"pubmed":["27801805"],"doi":["10.3390/ijms17111800"]}}